The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Apellis Pharmaceuticals Inc shares valued at $3,743,605 were sold by Deschatelets Pascal on Apr 08 ’24. At $54.17 per share, Deschatelets Pascal sold 69,107 shares. The insider’s holdings dropped to 1,115,983 shares worth approximately $62.19 million following the completion of this transaction.
Also, Sullivan Timothy Eugene sold 4,000 shares, netting a total of over 234,640 in proceeds. Following the sale of shares at $58.66 each, the insider now holds 93,338 shares.
Before that, Dunlop A. Sinclair had sold 18,681 shares from its account. In a trade valued at $1,068,161, the Director traded Apellis Pharmaceuticals Inc shares for $57.18 each. Upon closing the transaction, the insider’s holdings decreased to 18,681 shares, worth approximately $9.7 million.
As published in a research note from Jefferies on February 05, 2024, Apellis Pharmaceuticals Inc [APLS] has been rated up from a Hold to a Buy and the price target has been revised to $80 from $68. Analysts at Wells Fargo downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in mid December. As of November 09, 2023, Goldman has initiated its “Buy” rating for APLS. Earlier on November 02, 2023, Mizuho initiated its rating. Their recommendation was “a Neutral” for APLS stock.
Analyzing APLS Stock Performance
During the last five days, there has been a drop of approximately -0.57%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -6.90%. Shares of the company reached a 52-week high of $73.80 on 01/09/24 and a 52-week low of $53.19 on 03/20/24. A 50-day SMA is recorded $61.73, while a 200-day SMA reached $53.58. Nevertheless, trading volume fell to 1.05 million shares from 0.85 million shares the previous day.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 54.68, which, if violated, would cause prices to drop to 53.64. In the upper region, resistance lies at 57.31. The next price resistance is at 58.90. RSI (Relative Strength Index) is 43.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.75, which suggests the price will decrease in the coming days. Percent R is at 64.71%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on Mar 15, 2024 jumping by 0.32 million shares to 10.59 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 10.27 million shares. A jump of 3.02% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.54 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.54.
